MBX Biosciences, Inc. income statement MBX

Annual Quarterly

It recorded a net loss of $87.0 million. Diluted earnings per share were -$2.38.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Research and development
88
79
+37.9%
57
Selling, general and administrative
29
19
+75.3%
11
Operating income
-118
-98
-43.8%
-68
Pretax income
—
-87
—
Income tax
—
0
0
Net income
-104
-87
-40.5%
-62
Basic EPS
-2.41
-2.38
+59.1%
-5.82
Diluted EPS
-2.41
-2.38
+59.1%
-5.82
Weighted average shares, basic
43
37
+243.0%
11
Weighted average shares, diluted
43
37
+243.0%
11
Other measures
Depreciation and amortization
0
0
+1.6%
0
EBITDA
-118
-98
-43.9%
-68
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MBX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Carmel, IN
SEC filer status
, Emerging growth company
SEC CIK
1776111

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.